Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Formoterol inhalation - Mylan Specialty

Drug Profile

Formoterol inhalation - Mylan Specialty

Alternative Names: Formoterol fumarate inhalation solution - Dey; Nebulised formoterol fumarate - Dey; Perforomist; Perforomist Inhalation Solution

Latest Information Update: 21 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dey LP
  • Developer Mylan Specialty
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Apr 2015 The United States Court of Appeals for the Federal Circuit upholds Mylan's U.S. Patents on formoterol inhalation solution
  • 24 Jul 2013 Biomarkers information updated
  • 19 May 2009 Pooled efficacy & adverse events data from 2 phase III trials in Chronic obstructive pulmonary disease presented at the 105th International Conference of the American Thoracic Society (ATS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top